Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Applied Genetic Technologies Corporation (AGTC)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
0.6170-0.2071 (-25.13%)
At close: 04:00PM EDT
0.7430 +0.13 (+20.42%)
After hours: 07:58PM EDT
Advertisement
Full screen
Loading interactive chart...
  • GlobeNewswire

    AGTC Announces Key Appointments to Leadership Team

    AGTC Welcomes Eduardo Jacobo as the Sr. Vice President of GMP Manufacturing and Dr. David Jacobs as the Sr. Vice President of Clinical Research and Medical AffairsGAINESVILLE, Fla. and CAMBRIDGE, Mass., June 08, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited

  • GlobeNewswire

    AGTC to Present Three-Month Interim Results from the SKYLINE Clinical Trial of AGTC-501 for the Treatment of X-Linked Retinitis Pigmentosa at the 45th Macula Society Annual Meeting

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 06, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical-stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced an encore presentation of interim data from its ongoing Phase 2 Skyline trial of AGTC-501, a recombinant AAV viral vector-based

  • GlobeNewswire

    AGTC Announces Age-Related Macular Degeneration Scientific Advisory Board

    GAINESVILLE, Fla., and CAMBRIDGE, Mass., June 01, 2022 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq: AGTC), a clinical stage biotechnology company focused on the development of adeno-associated virus (AAV)-based gene therapies for the treatment of rare and debilitating diseases with an initial focus on inherited retinal diseases, today announced the formation of a scientific advisory board (SAB) comprised of leading experts in age-related macular degeneration (AMD). The S

Advertisement
Advertisement